Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Article
Liu, David, Schilling, Bastian
, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham
, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix, Izar, Ben, Garraway, Levi, Regev, Aviv, Flaherty, Keith, Paschen, Annette, Van Allen, Eliezer M. and Schadendorf, Dirk
(2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Nature Medicine 25 (12), pp. 1916-1927.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Nature Medicine | ||||
| Publisher | Nature | ||||
| Place of Publication | NEW YORK | ||||
| Volume | 25 | ||||
| Number of Issue or Book Chapter | 12 | ||||
| Page Range | pp. 1916-1927 | ||||
| Date | 2019 | ||||
| Date of publication | 03 Sep 2021 09:33 | ||||
| Institutions | Medicine > Lehrstuhl für Dermatologie und Venerologie | ||||
| Identification Number |
| ||||
| Keywords | PD-1 BLOCKADE; OPEN-LABEL; CTLA-4 BLOCKADE; RESISTANCE; MUTATIONS; PEMBROLIZUMAB; IPILIMUMAB; SIGNATURES; NIVOLUMAB; MULTICENTER; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 48000 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric